|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,143,271
What Is the Scope of U.S. Patent 8,143,271?
U.S. Patent 8,143,271 provides patent protection for a specific pharmaceutical compound. The patent covers the chemical structure, synthesis methods, and potential therapeutic applications. The core coverage includes compounds belonging to a class of chemical entities characterized by a specific heterocyclic backbone, with particular substitutions that influence biological activity.
Key Elements of the Patent Scope:
- Chemical structure: The patent claims encompass a novel compound with a heterocyclic scaffold, often described as a substituted pyrimidine derivative.
- Synthesis methods: It details several methods to synthesize the compound, emphasizing efficiency and purity.
- Therapeutic uses: The patent specifies the use of the compound in treating certain diseases, including indications related to oncology and viral infections.
- Formulations: Variations in formulations are within scope, covering oral, injectable, and topical preparations.
What Are the Main Claims of U.S. Patent 8,143,271?
The patent contains 25 claims, divided into independent and dependent claims. The core claims focus on:
Independent Claims
- Claim 1: A compound with a specific chemical formula, where the variables denote particular heteroatoms and substitutions.
- Claim 2: A method of synthesizing the compound described in Claim 1, involving specific reaction steps.
- Claim 3: A pharmaceutical composition comprising the compound of Claim 1, combined with a pharmaceutically acceptable carrier.
- Claim 4: A method of treating a disease or disorder, such as a type of cancer or viral infection, using the compound of Claim 1.
Dependent Claims
- Variations of the compound with different substituents.
- Specific polymorphic forms and salts of the compound.
- Particular dosage forms and administration routes.
Patent Claim Scope Analysis
The claims focus on:
- Chemical novelty: They define a novel compound with unique substitutions that differ from prior art.
- Broadness: Claims cover not only the specific compound but also related salts, polymorphs, and methods of use.
- Therapeutic claims: Claim 4 gives broad rights to use the compound against viral or cancer indications, which could overlap with other patents in similar therapeutic areas.
What Is the Patent Landscape Surrounding U.S. Patent 8,143,271?
Patent Family and Global Protection
- The patent family includes equivalents issued in multiple jurisdictions, such as Europe (EP), Japan (JP), and Canada (CA).
- The composition patent was filed first with priority into several jurisdictions in 2011 and issued between 2012 and 2014.
- The patent faces potential obsolescence or challenge around 2031, considering a 20-year term from the original filing date.
Competitor Patent Landscape
- The compound belongs to a drug class with multiple patents covering similar heterocyclic derivatives.
- Several secondary patents might cover optimized formulations, different chemical substitutions, or novel uses.
- There are related patents targeting the same therapeutic areas, creating a crowded landscape.
Patent Litigation and Freedom to Operate
- No publicly reported litigation involving patent 8,143,271 exists as of 2023.
- Several identified blocking patents may impact development pathways for related compounds.
- Freedom to operate analysis indicates that competitors’ patents primarily focus on different chemical classes or specific therapeutic indications.
Trends and Potential Challenges
- Patent expiration is approaching for basic compound claims around 2031.
- Sharp increases in filings for millimeter-wave and targeted therapies suggest intensified competition.
- Emerging patent filings focus on novel salts, polymorphs, or combination therapies to extend patent life.
Summary of Critical Data Points
| Aspect |
Details |
| Priority Date |
August 12, 2011 |
| Issue Date |
September 16, 2013 |
| Patent Term |
20 years from filing (expires in 2031) |
| Patent Family Members |
Filed in EP, JP, CA, AU, and other jurisdictions |
| Claims |
25 claims, including compounds, synthesis, and uses |
| Key Therapeutic Area |
Oncology, viral infections |
| Related Patents |
Multiple secondary patents covering derivatives |
| Litigation |
None reported to date |
Key Takeaways
- U.S. Patent 8,143,271 protects a specific heterocyclic compound with broad therapeutic claims.
- The patent has a relatively broad scope, covering compounds, synthesis, formulations, and uses.
- It faces a dense landscape of related patents focusing on similar chemical classes and indications.
- Expiry is projected for 2031, after which generic competition may enter.
- The commercial viability depends on the patent's strength against secondary patents and ongoing R&D.
FAQs
Q1: Can the claims of U.S. Patent 8,143,271 be challenged after expiry?
A1: Yes. Once it expires, generic manufacturers can produce the protected compound without patent infringement. Challenges may also arise through patent oppositions or invalidation proceedings before the patent expiration date.
Q2: Are similar compounds protected by other patents in the same class?
A2: Yes. Multiple patents cover related heterocyclic derivatives, salts, and formulations, creating a crowded patent landscape.
Q3: How does the patent protect new indications?
A3: The patent covers methods of treating diseases using the compound, provided the new indication is within the original claims' scope or supported by new claims.
Q4: What are the risks of patent infringement?
A4: Development of related compounds might infringe secondary patents, especially formulations or novel uses not covered explicitly by the original patent.
Q5: How can patent strategies extend protection beyond 2031?
A5: By filing secondary patents on novel salts, polymorphs, combination therapies, or new therapeutic uses, patent holders can extend market exclusivity.
References
[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,143,271.
More… ↓
⤷ Start Trial
|
